Factors influencing islet of Langerhans graft function and monitoring

Clinica Chimica Acta

Volumn 310, Issue 1, 2001, Pages 3-16

  Pileggi, Antonello ^a   Ricordi, Camillo ^a   Alessiani, Mario ^b   Inverardi, Luca ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autoimmunity; Graft function; Islets of Langerhans; Monitoring; Rejection; Transplantation

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN;

AUTOIMMUNITY; CELL FATE; CELL FUNCTION; CELL ISOLATION; CELL TRANSPLANTATION; CELL VIABILITY; CONFERENCE PAPER; GLYCOSYLATION; GRAFT REJECTION; HUMAN; IMPLANT; INFLAMMATION; INNER CELL MASS; INSULIN DEPENDENT DIABETES MELLITUS; MONITORING; ORGAN TRANSPLANTATION; PANCREAS ISLET; PRIORITY JOURNAL;

AUTOANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 0034907589     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00503-4     Document Type: Conference Paper

References (159)

1. Cell transplantation
2. A method for obtaining suspensions of living cells from fixed tissues and for the plating out of individual cells
3. The collagenase (k toxin) of Clostridium welchii type A
4. The pathogenesis of insulin-dependent diabetes mellitus
5. Insulin-dependent diabetes mellitus
6. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
7. Reversal of lesions of diabetic nephropathy after pancreas transplantation
8. Current status of pancreas transplantation for the treatment of type 1 diabetes mellitus
9. Pancreas transplants for United States and non-United States cases as reported to the International Transplant Registry and to the United Network of Organ Sharing
10. Results, research priorities, and reasons for optimism: Islet transplantation for patients with type 1 diabetes
11. Human islet autotransplantation following pancreatectomy
12. Autologous islet transplantation to prevent diabetes after pancreatic resection
13. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement
14. Human islet isolation and allotransplantation in 22 consecutive cases
15. Insulin independence after islet-liver transplantation for metastatic neuroendocrine pancreatic tumor
16. Combined liver-islet transplantation after epigastric exenteration in carcinoma of Vater's ampulla
17. Insulin independence for 58 months following pancreatic islet cell transplantation in a patient undergoing upper abdominal exenteration
18. Results of human islet allotransplantation in cystic fibrosis and type I diabetic patients
19. Clinical islet transplantation experience of the University of California Islet Transplant Consortium
20. Simultaneous islet-liver transplantation: Preliminary results from the UC Islet Transplantation Consortium
21. Human islet allografts in patients with type 2 diabetes undergoing liver transplantation
22. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
23. Weitere mittheilungen uber den diabetes mellitus nach exstirpation des pankreas
24. Notes on diabetes treated with extract and by grafts of sheep's pancreas
25. Isolation and culture of the islets of Langerhans of the guinea pig
26. Method for the isolation of intact islets of Langerhans from the rat pancreas
27. Transplantation of intact pancreatic islets in rats
28. Preparation of viable islet cells from dogs by a new method
29. A method for large scale high yield isolation of canine pancreatic islets of Langerhans
30. A method for isolation of islets of Langerhans from the human pancreas
31. A method for the mass isolation of islets from the adult pig pancreas
32. An automated method for the isolation of human pancreatic islets
33. Human islet transplantation: A preliminary report
34. Insulin independence after islet transplantation into type I diabetic patient
35. Long-term function (6 years) of islet allografts in type 1 diabetes
36. Portal vein immunosuppressant levels and islet graft toxicity
37. The effect of prednisone on pancreatic islet autografts in dogs
38. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
39. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation
40. Transplantation tolerance: A look at the nonhuman primate literature in the light of modern tolerance theories
41. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies
42. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4
43. Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts
44. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice
45. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
46. The correlation between donor characteristics and the success of human islet isolation
47. Pancreas procurement for islet isolation and pancreas storage prior to islet isolation
48. Cold ischemic tolerance of human pancreas: Assessment of islet recovery and function
49. Variables in organ donors that affect the recovery of human islets of Langerhans
50. Human islet cell transplantation: New perspectives for an old challenge
51. Anatomy and physiology of islets of Langerhans
52. Pancreatic islet cells
53. Exocrine contamination impairs implantation of pancreatic islets transplanted beneath the kidney capsule
54. Immunological characteristics of purified pancreatic islet grafts
55. Isokinetic gradient centrifugation prolongs survival of pig islets xenografted into mice
56. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft
57. Improved human islet isolation using a new enzyme blend, liberase
58. Adult islet purification
59. Structural and functional changes resulting from islet isolation lead to islet cell death
60. Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation
61. DNA fragmentation is an early event in cytokine-induced islet beta-cell destruction
62. Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation
63. Endotoxin impairs the engraftment of rat islets transplanted beneath the kidney capsule of C57BL/6-mice
64. Endotoxin-mediated activation of cytokine production in human PBMCs by collagenase and Ficoll
65. Endotoxin activity of collagenase in human islet transplantation
66. Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis
67. Evidence for IL-6 production by and effects on the pancreatic beta-cell
68. Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production
69. IL-1 produced and released endogenously within human islets inhibits β cell function
70. Endocrinometabolic effects of whole versus segmental pancreas allotransplantation in diabetic patients - A two-year follow-up
71. Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors
72. Preserved insulin secretion and insulin independence in recipients of islet autografts
73. Automated islet isolation from human pancreas
74. New protocol toward prevention of early human islet allograft failure
75. Improved survival of single donor islet allograft in IDDM recipients by refined peritransplant management
76. Vulnerability of islets in the immediate posttransplantation period: Dynamic changes in structure and function
77. Influence of experimental hyperglycemia on microvascular blood perfusion of pancreatic islet isografts
78. Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts
79. Transplantation of allogeneic islets of Langerhans in the rat liver: Effects of macrophage depletion on graft survival and microenvironment activation
80. The "injury response": A concept linking nonspecific injury, acute rejection, and long-term transplant outcomes
81. Morphological evidence for the existence of nitric oxide and carbon monoxide pathways in the rat islets of Langerhans: An immunocytochemical and confocal microscopical study
82. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse
83. Superoxide dismutase in human islets of Langerhans
84. Antioxidant enzyme activities in IDD-prone and IDD-resistant mice: A comparative study
85. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues
86. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells
87. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans: Evidence for the beta-cell as a source and site of action of nitric oxide
88. IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes
89. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus
90. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: Protective effects of sCR1 and heparin
91. Role of humoral immunity in pancreatic islet allo- and xenograft rejection
92. Isolated human pancreatic islets in vitro activate human complement
93. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation?
94. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass
95. Specific inhibition of macrophage-derived proinflammatory cytokine synthesis with a tetravalent guanylhydrazone CNI-1493 accelerates early islet graft function posttransplant
96. Glucose turnover and insulin sensitivity in rats with pancreatic islet transplants
97. Metabolic assessment of posttransplant islet function in humans; methodological considerations and possible pittfalls: A lesson from pancreas transplantation
98. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus
99. Peptides and other neuronal markers in transplanted pancreatic islets
100. Autonomic regulation of islet hormone secretion - Implications for health and disease
101. Intraportal transplantation of pancreatic islets into livers of diabetic rats. Reinnervation of islets and regulation of insulin secretion by the hepatic sympathetic nerves
102. Dynamics of glucose-induced insulin release from mouse islets transplanted under the kidney capsule
103. Diminished inhibitory effect of noradrenaline on insulin release from mouse islets transplanted to kidney
104. Loss of cholinergic potentiating responsiveness in mouse islets transplanted to the kidney
105. Effects of UK-14,304, noradrenaline, and propranolol on insulin release from transplanted mouse islets
106. Cephalic-phase insulin secretion in normal and pancreatic islet-transplanted rats
107. Cephalic-phase insulin and glucagon release in normal subjects and in patients receiving pancreas transplantation
108. Insulin secretory patterns and blood glucose homeostasis after islet allotransplantation in IDDM patients: Comparison with segmental- or whole-pancreas transplanted patients through a long term longitudinal study
109. Recurrent diabetes mellitus in the pancreas iso- and allograft: A light and electron microscopic and immunohistochemical analysis of four cases
110. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation
111. Recurrence of disease in pancreas transplants
112. Spontaneous diabetes in rats: Destruction of islets is prevented by immunological tolerance
113. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice
114. Expression of genetically determined diabetes and insulitis in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells: Transfer of diabetes and insulitis to nondiabetic (NOD×B10) F1 mice with bone marrow cells from NOD mice
115. The effect of H-2 compatibility on pancreatic beta cell survival in the nonobese diabetic mouse
116. Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice
117. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody
118. Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: Evidence of donor chimerism
119. Occurrence and prevention of graft-vs-host disease after pancreaticoduodenal transplantation in the BB rat
120. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation
121. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes
122. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts
123. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation
124. Mean amplitude of glycemic excursions, a measure of diabetic instability
125. Continued function of pancreatic islets after transplantation in type I diabetes
126. What you always wanted to know about HbA1c
127. Quality control, quality assessment of laboratory tests, HbA1c
128. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT)
129. Hypoglycemia in the diabetes control and complications trial
130. Intraportal islet allografts: The use of a stimulation index to represent functional results
131. Pancreatic endocrine function in recipients of segmental and whole pancreas transplantation
132. Successful islet autotransplantation in humans: Functional insulin secretory reserve as an estimate of surviving islet cell mass
133. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus
134. Reduction of insulin resistance by combined kidney-pancreas transplantation in type 1 (insulin-dependent) diabetic patients
135. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene
136. The relative contribution of insulin secretory capacity, insulin action, and incretins to metabolic control after islet transplantation in dogs
137. Glucoregulation after canine islet transplantation: Contribution of insulin secretory capacity, insulin action, and the entero-insular axis
138. Islet transplantation in IDDM patients
139. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients
140. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus: Report of the first international workshop for standardization of T cell assays
141. Sensitization to HLA antigens in islet recipients with failing transplants
142. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts
143. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation
144. Prospects and applicability of molecular diagnosis of allograft rejection
145. Recognition of islet-directed peripheral blood lymphocytes in vitro before rejection of allogeneic grafted islets
146. Transplantation of porcine fetal islet-like cell clusters to three diabetic patients
147. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
148. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue
149. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes
150. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction
151. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets
152. HO-1 upregulation protects the pancreatic beta cell line β TC3 from cytokine and Fas-induced apoptosis
153. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: Graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft
154. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells